Finding. Rubicon turns off the UVRAG-containing PI3KC3-C2 complex by grabbing a pose of the shared BECN1 BARA domain that UVRAG creates. It does not need to touch UVRAG, and ATG14 does not have to block the site on C1. Cryo-EM of the bound complex, compared with free C2 and C1, makes that selectivity geometric. Break the interface with mutations and mitophagy in human epithelial cells rises to Rubicon-knockout levels. Do the same in Rubicon-overexpressing hippocampal neurons and lysosomal flux returns to wild type. The entire Rubicon brake on autophagy and the endolysosomal network, in these assays, is PI3KC3-C2 suppression.
Why this paper matters
Rubicon is already the named antagonist you would love to lift in diseases with stuck autophagy and endolysosomes, Parkinson’s included. What was missing was why it hits C2 and spares the ATG14-only C1 complex, and whether that one interaction explains the biology. This structure-plus-mutant paper answers both.
For mitochondria, the payoff is the mitophagy phenocopy. You do not need to delete Rubicon if you can occupy this surface. That is a drug-design sentence with an organelle clearance readout.
What they actually measured
High-resolution cryo-EM of C2 plus Rubicon’s PI3K-binding domain, versus unbound C2 and C1. Binding only to BECN1 BARA. Selectivity attributed to a UVRAG-induced BARA conformation. Targeted interface mutations: epithelial mitophagy up to KO; neuronal lysosomal flux back to wild type. The authors’ claim is completeness: C2 inhibition fully accounts for Rubicon’s negative regulation in these pathways.
Completeness is always a fighting word. It holds for the assays they ran. It does not inventory every Rubicon protein–protein contact in a neuron.
How to read the score
Low-to-mid eighties. Atomic mechanism, selectivity logic, and a mitophagy-level genetic phenocopy. Confidence is high for the structural claim, medium for “fully accounts” as biology, low for Parkinson therapy. Score 84.
What to do with it
If you design autophagy or mitophagy upregulators, this interface is the coordinate set. Pull the maps and the mutant mitophagy data. Do not write a Parkinson’s trial note. The directional implication is that Rubicon is a conformational reader of C2, and that lifting that read is enough to restore mitophagy and lysosomal flux in the systems tested.